Most patients do well on topical therapy, but innovation in IOP-lowering drops remains essential.
Kuldev Singh, MD, MPH
Advertisement
Kuldev Singh, MD, MPH, is professor of ophthalmology and chief of the glaucoma division in the Department of Ophthalmology at Stanford University School of Medicine in Palo Alto, California.
Articles by Kuldev Singh, MD, MPH
Advertisement
Latest Updated Articles
Physician perspective: Glaucoma eye drops are here to stayFebruary 12th 2026
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
DSLT for glaucoma and ocular hypertension: Real-world outcomes in 218 eyes
2
First patient dosed in phase 3 pivotal cohort of LIGHTHOUSE trial evaluating ATSN-201 for X-linked retinoschisis
3
ARPA-H funds tear-duct biosensor system for dry eye, systemic disease
4
NCX 470 gains positive regulatory feedback in China ahead of US NDA submission
5